Aytu Biopharma (AYTU) Accumulated Expenses (2012 - 2026)

Since fiscal Q4 2013, Aytu Biopharma has reported Accumulated Expenses for 43 quarters.

• Annual Accumulated Expenses shows a five-year compound annual growth rate of -9.3% (FY2021 to FY2026).
• In prior fiscal years, Aytu Biopharma's Accumulated Expenses was $38.16 million in FY2025 (+0.1%), $38.14 million in FY2024 (-18.5%), $46.8 million in FY2023 (+5.9%) and $44.19 million in FY2022 (-22.8%).
• Quarterly Accumulated Expenses has run from a low of $33.72 million in fiscal Q1 2025 to a high of $54.38 million in fiscal Q1 2022 over five years.
• On a year-over-year basis, Accumulated Expenses increased in three of the last eight quarters, with an average decline of 5.8%.
• The strongest year-over-year quarter for Accumulated Expenses in the past five years was fiscal Q1 2022, with growth of 525.6%; the weakest was fiscal Q1 2023, with a decline of 23.8%.
• According to Business Quant data, Accumulated Expenses for the three prior fiscal quarters was $34.27 million (Q3 2026), $40.16 million (Q2 2026) and $36.7 million (Q1 2026).